An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease

Trial Profile

An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Ferumoxytol (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AMAG Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2016 Status changed from active, no longer recruiting to discontinued as several factors contributed to significant challenges in enrollment and led the sponsor to discontinue the AMAG-FER-CKD-253 study as designed.
    • 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top